글로벌 면역 조절제 시장 – 2030년까지의 산업 동향 및 예측

면역 조절제 시장 분석 및 규모

전 세계적으로 크론병 치료를 위한 초기 면역 조절제 요법 채택이 증가하면서 면역 조절제 시장 성장을 견인하는 주요 요인 중 하나가 되었습니다. 천식, 알레르기 질환, 암, 다발성 경화증 과 같은 만성 질환의 발생률이 증가하고 면역 조절제 연구 개발에 참여하는 회사의 효과적인 제품 파이프라인이 제공되면서 시장 성장이 가속화되었습니다. 류마티스 관절염 과 같은 면역 질환 치료와 관련하여 충족되지 않은 임상적 요구가 높고 라퀴니모드, 오자니모드와 같은 면역 치료제 개발을 위한 진행 중인 임상 시험 수가 증가하면서 시장에 더 많은 영향을 미쳤습니다. 또한 인구 증가, 의료비 지출 급증, 의료 인프라 개선, 인식 증가, 생명 공학 및 제약 부문의 확장으로 2023년에서 2030년까지의 예측 기간 동안 시장 참여자에게 수익성 있는 기회가 확대되었습니다.

Data Bridge Market Research는 2022년에 2억 1,710만 달러였던 면역 조절제 시장이 2030년까지 3억 6,470만 달러로 급증할 것으로 분석했으며, 예측 기간 동안 6.7%의 CAGR을 경험할 것으로 예상합니다. 이는 시장 가치를 나타냅니다. "병원"은 병원에서 증가하는 사례로 인해 면역 조절제 시장의 최종 사용자 세그먼트를 지배합니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

면역 조절제 시장 범위 및 세분화

시장 정의

면역 조절제는 면역 체계를 자극하거나 억제하고 면역 체계를 변화시켜 면역 반응의 변화를 초래하는 유형의 약물을 말합니다. 이러한 약물은 면역 반응을 보이는 이물질 항원과 반응하는 항체의 생성을 줄입니다. 면역 억제제와 면역 자극제는 면역 조절제에 따라 특징지어집니다.

글로벌 면역 조절제 시장 역학

운전자

• 만성질환 발생률 증가

천식, 알레르기 질환, 암, 다발성 경화증 등 만성 질환의 발생률이 증가하고, 면역 조절제 연구 개발에 참여하는 기업의 효과적인 제품 파이프라인이 확보됨에 따라 시장 성장이 가속화됩니다.

천식, 알레르기 질환, 암, 다발성 경화증을 포함한 만성 질환의 증가 발생률. 또한 면역 조절제 산업의 성장에 기여하는 요인 중 일부에는 장기 이식의 만연, 크론병 치료를 위한 조기 면역 조절제 요법의 채택 증가, 염증성 장 질환에 대한 인식 증가, 자가면역 질환의 증가, 약물 내성 증가가 포함되며, 이로 인해 면역 조절제 사용이 증가하고 있습니다.

• 노령 인구의 증가

Expanding geriatric population worldwide is predicted to favour the immunomodulators as this population is more prone to develop diseases. The number of persons above 65 years is projected to double in the coming years. The old age people are prone to various chronic diseases such as cardiovascular diseases, endovascular diseases, infectious diseases, and dental disorders, which can foster the demand for the immunomodulators cases across the globe.

According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.

• Growing awareness as well as expansion of biotechnology and pharmaceutical sectors

Growing awareness levels amongst patients and physicians pertaining to the applications of monoclonal therapy in immunomodulation is presumed to be contributing toward market growth. The aforementioned factor is believed to boost the adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators market over the forecast period.

Moreover, the demand for immunomodulators is not only limited to developed countries but is also being witnessed in the developing countries which will further act as driver that will lead to the growth of the immunomodulators market in the above mentioned projected timeframe.

Opportunities

Furthermore, key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the rising demand for drugs has significantly heightened the need for new drug development via extensive clinical trials. Manufacturers are now focusing on remodelling their drug development processes in an attempt to cater to patient needs across the globe. High prevalence of cancer and chronic disorders such as HIV/AIDs, asthma, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, and other autoimmune diseases is considered one of the major causes of morbidity & mortality, particularly in patients with compromised immune systems.

Increasing advancement in technology and rising number of innovations along with rising product approvals which will further contribute by generating immense opportunities that will further expand the market's growth rate in the future.

Restraints/Challenges

On the other hand, high costs associated with immunomodulator products and stringent regulatory policies for approval of immunomodulators antibodies which will likely to act as market restraints factor for the growth of the immunomodulators in the above mentioned projected timeframe. Moreover, adverse effects of immunomodulator drugs including pain, inflammation, and epilepsy will projected to become the biggest and foremost challenge for the growth of the market in the forecast period of 2023-2030.

This immunomodulators market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunomodulators market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2022, Sun Pharma launched a dry eye treatment product in Canada named CEQUA, a calcineurin inhibitor immunomodulator that uses nano micellar (NCELL) technology to improve the bioavailability and physicochemical stability of cyclosporine to promote the ocular tissue penetration.
• In February 2021 Merck announced the acquisition of Pandion Therapeutics in which the acquisition adds the pipeline of candidates targeting a broad range of Autoimmune Diseases. Pandion has used its TALON technology to build a strong pipeline of candidates that aim to regulate the immune response and could be used to treat a variety of autoimmune conditions.

Global Immunomodulators Market Scope

The immunomodulators market is segmented on the basis of product, application, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Immunosuppressants
• Calcineurin Inhibitors
• Antibodies
• Antimetabolites
• Glucocorticoids
• Others
• Immunostimulants
• Vaccines
• Antibodies
• Others
• Others

Application

• Respiratory
• Human Immunodeficiency Virus (HIV)
• Oncology
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Global Immunomodulators Market Regional Analysis/Insights

The immunomodulators market is analysed and market size insights and trends are provided by country, product, application, end users and distribution channel.

The countries covered in the immunomodulators market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.  

North America dominates the immunomodulators market because of the presence of a large diseased population and surge the demand for immunomodulatory therapy within the region

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 owing to the presence of supportive government initiatives in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The immunomodulators market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for immunomodulators market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the immunomodulators market. The data is available for historic period 2010-2021.

Competitive Landscape and Immunomodulators market Share Analysis

The immunomodulators market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunomodulators market.

Some of the major players operating in the immunomodulators market are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Services, Inc.(U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Amgen Inc.(U.S.)
• Novartis AG (Switzerland)
• GlaxoSmithKline plc.(U.K.)
• Merck & Co., Inc.(U.S.)
• Squarex.(U.S.)
• BioRap Technologies LTD(이스라엘)
• 파이저 주식회사(미국)
• NPO Petrovax Pharm(러시아)
• ResoTher Pharma(덴마크)
• InDex Pharmaceuticals Holding AB(스웨덴)
• Step-Pharma(프랑스)
• 스프링 뱅크 제약(미국)
• Horizon Therapeutics plc(아일랜드)
• iTeos(독일)
• BioNTech SE(독일)
• 제리아제약 주식회사(일본)
• Atox Bio(이스라엘)

SKU-50214